Abstract
Background: Heart failure (HF) is a clinical syndrome that is treated with multiple medications,
putting patients at risk of drug therapy problems (DTPs). DTPs are a great concern in health care
due to their significant impact on morbidity, mortality, and higher costs associated with health care.
Aims: This study aimed to assess the prevalence and factors associated with DTPs related to
cardiovascular agents among HF patients hospitalized at the Mbarara Regional Referral Hospital.
Methods: A prospective observational study was conducted among hospitalized HF patients from
November 2021 to January 2022. A total of 118 patients diagnosed with HF were recruited. Patient
file reviews and interviewer-administered questionnaires were used for data collection. Univariate
and multivariate logistic regressions were employed to determine factors associated with the DTPs.
Result: A total of 118 HF patients with a median age of 43 years were included in this study.
Among them, 57 participants experienced a total of 81 DTPs with a prevalence of 48.3%. “Dosage
too high” was the most common DTP (23, 28.3%) followed by “needs additional drug therapy”
(22, 27.2%). Hospitalized HF patients aged 60 years and above (adjusted odds ratio [AOR]: 4.1;
95% confidence interval [CI]: [1.5 – 10.3]; P = 0.012) and taking more than five medications during
their hospital stay (AOR: 2.92; 95% CI: [1.5 – 7.6]; P = 0.029) were significantly associated with
experiencing at least one DTP.
Conclusion: Almost half of the hospitalized HF patients experienced at least one DTP during
their hospital stay. “Dosage too high” and “needs additional drug therapy” were the most common
DTPs. Hospitalized HF patients with poly-pharmacy (taking more than five cardiovascular agents)
and aged above 60 were more likely to have DTPs. It is noted that patient groups who are at
risk require follow-ups to improve the treatment outcome, and incorporation of clinical pharmacy
service could be part of the solution.
Relevance for Patients: This study identifies the factors associated with the development of
DTP to facilitate the development and implementation of prevention strategies for the commonly
identified DTPs.
DOI: https://doi.org/10.36922/jctr.23.00137
Author affiliation
1Department of Pharmacy, Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda
2Department of Clinical
Pharmacy, School of Pharmacy, Hawassa University, Hawassa, Ethiopia
3Department of Internal Medicine, School of Medicine, Hawassa
University, Hawassa, Ethiopia
4Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy, Kampala International
University, Ishaka, Uganda
*Corresponding author:
Efrata Ashuro Shegena
Department of Pharmacy, Faculty of Medicine,
Mbarara University of Science and Technology,
Mbarara, Uganda.
Email: ashuroefrata@gmail.com
Downloads
Full-text PDF
